|
1
|
Sherr CJ: Principles of tumor suppression.
Cell. 116:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsuda S, Kawamura-Tsuzuku J, Ohsugi M,
et al: Tob, a novel protein that interacts with p185erbB2, is
associated with anti-proliferative activity. Oncogene. 12:705–713.
1996.PubMed/NCBI
|
|
3
|
Guardavaccaro D, Corrente G, Covone F, et
al: Arrest of G(1)-S progression by the p53-inducible gene PC3 is
Rb dependent and relies on the inhibition of cyclin D1
transcription. Mol Cell Biol. 20:1797–1815. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ikematsu N, Yoshida Y, Kawamura-Tsuzuku J,
et al: Tob2, a novel anti-proliferative Tob/BTG1 family member,
associates with a component of the CCR4 transcriptional regulatory
complex capable of binding cyclin-dependent kinases. Oncogene.
18:7432–7441. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rouault JP, Rimokh R, Tessa C, et al:
BTG1, a member of a new family of antiproliferative genes. EMBO J.
11:1663–1670. 1992.PubMed/NCBI
|
|
6
|
Yoshida Y, Nakamura T, Komoda M, et al:
Mice lacking a transcriptional corepressor Tob are predisposed to
cancer. Genes Dev. 17:1201–1206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O’Malley S, Su H, Zhang T, Ng C, Ge H and
Tang CK: TOB suppresses breast cancer tumorigenesis. Int J Cancer.
125:1805–1813. 2009.
|
|
8
|
Yanagie H, Tanabe T, Sumimoto H, et al:
Tumor growth suppression by adenovirus-mediated introduction of a
cell-growth-suppressing gene tob in a pancreatic cancer model.
Biomed Pharmacother. 63:275–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito Y, Suzuki T, Yoshida H, et al:
Phosphorylation and inactivation of Tob contributes to the
progression of papillary carcinoma of the thyroid. Cancer Lett.
220:237–242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu J, Liu P, Cui X, et al: Identification
of novel subregions of LOH in gastric cancer and analysis of the
HIC1 and TOB1 tumor suppressor genes in these subregions. Mol
Cells. 32:47–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tzachanis D, Freeman GJ, Hirano N, et al:
Tob is a negative regulator of activation that is expressed in
anergic and quiescent T cells. Nat Immunol. 2:1174–1182. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiong B, Rui Y, Zhang M, et al: Tob1
controls dorsal development of zebrafish embryos by antagonizing
maternal beta-catenin transcriptional activity. Dev Cell.
11:225–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Powell SM, Harper JC, Hamilton SR,
Robinson CR and Cummings OW: Inactivation of Smad4 in gastric
carcinomas. Cancer Res. 57:4221–4224. 1997.PubMed/NCBI
|
|
14
|
Wang LH, Kim SH, Lee JH, et al:
Inactivation of SMAD4 tumor suppressor gene during gastric
carcinoma progression. Clin Cancer Res. 13:102–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kolligs FT, Bommer G and Goke B:
Wnt/beta-catenin/tcf signaling: a critical pathway in
gastrointestinal tumorigenesis. Digestion. 66:131–144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jung HS, Erkin OC, Kwon MJ, et al: The
synergistic therapeutic effect of cisplatin with human
papillomavirus E6/E7 short interfering RNA on cervical cancer cell
lines in vitro and in vivo. Int J Cancer. 130:1925–1936. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kwon MJ, Oh E, Lee S, et al:
Identification of novel reference genes using multiplatform
expression data and their validation for quantitative gene
expression analysis. PLoS One. 4:e61622009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gildea JJ, Harding MA, Gulding KM and
Theodorescu D: Transmembrane motility assay of transiently
transfected cells by fluorescent cell counting and luciferase
measurement. Biotechniques. 29:81–86. 2000.PubMed/NCBI
|
|
19
|
Tian X, Du H, Fu X, Li K, Li A and Zhang
Y: Smad4 restoration leads to a suppression of Wnt/beta-catenin
signaling activity and migration capacity in human colon carcinoma
cells. Biochem Biophys Res Commun. 380:478–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Novak A and Dedhar S: Signaling through
beta-catenin and Lef/Tcf. Cell Mol Life Sci. 56:523–537. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Resende C, Thiel A, Machado JC and
Ristimaki A: Gastric cancer: basic aspects. Helicobacter. 16(Suppl
1): 38–44. 2011. View Article : Google Scholar
|
|
22
|
Athar M, Elmets CA and Kopelovich L:
Pharmacological activation of p53 in cancer cells. Curr Pharm Des.
17:631–639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiao Y, Ge CM, Meng QH, Cao JP, Tong J and
Fan SJ: Adenovirus-mediated expression of Tob1 sensitizes breast
cancer cells to ionizing radiation. Acta Pharmacol Sin.
28:1628–1636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schwarte-Waldhoff I, Klein S,
Blass-Kampmann S, et al: DPC4/SMAD4 mediated tumor suppression of
colon carcinoma cells is associated with reduced urokinase
expression. Oncogene. 18:3152–3158. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen W, Tao GQ, Li DC, Zhu XG, Bai X and
Cai B: Inhibition of pancreatic carcinoma cell growth in vitro by
DPC4 gene transfection. World J Gastroenterol. 14:6254–6260. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alpizar-Alpizar W, Nielsen BS, Sierra R,
et al: Urokinase plasminogen activator receptor is expressed in
invasive cells in gastric carcinomas from high- and low-risk
countries. Int J Cancer. 126:405–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pollock CB, Rodriguez O, Martin PL, et al:
Induction of metastatic gastric cancer by peroxisome
proliferator-activated receptordelta activation. PPAR Res.
2010:5717832010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawasaki K, Hayashi Y, Wang Y, et al:
Expression of urokinase-type plasminogen activator receptor and
plasminogen activator inhibitor-1 in gastric cancer. J
Gastroenterol Hepatol. 13:936–944. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okusa Y, Ichikura T, Mochizuki H and
Shinomiya N: Urokinase type plasminogen activator and its receptor
regulate the invasive potential of gastric cancer cell lines. Int J
Oncol. 17:1001–1005. 2000.PubMed/NCBI
|
|
30
|
Choi BD, Jeong SJ, Wang G, et al:
Secretory leukocyte protease inhibitor is associated with MMP-2 and
MMP-9 to promote migration and invasion in SNU638 gastric cancer
cells. Int J Mol Med. 28:527–534. 2011.PubMed/NCBI
|
|
31
|
Jiao Y, Sun KK, Zhao L, Xu JY, Wang LL and
Fan SJ: Suppression of human lung cancer cell proliferation and
metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta
Pharmacol Sin. 33:250–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Persad S, Troussard AA, McPhee TR,
Mulholland DJ and Dedhar S: Tumor suppressor PTEN inhibits nuclear
accumulation of beta-catenin and T cell/lymphoid enhancer factor
1-mediated transcriptional activation. J Cell Biol. 153:1161–1174.
2001. View Article : Google Scholar : PubMed/NCBI
|
